Not applicableWithdrawnNCT06554730What this trial is testingMSD Belzutifan PASWho this might be right forVon Hippel Lindau Disease Merck Sharp & Dohme LLC
Early research (Phase 1)Looking for participantsNCT07300241What this trial is testingOpen-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell CarcinomaWho this might be right forClear Cell Renal Cell CarcinomaRenal Cell CarcinomaRCC+6 more Neomorph, Inc 30
Testing effectiveness (Phase 2)Study completedNCT03108066What this trial is testingMK-3795 (PT2385) for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma (MK-3795-003)Who this might be right forVHL Gene MutationVHLVHL Syndrome+8 more Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) 4
Early research (Phase 1)Looking for participantsNCT06553339What this trial is testingHS-10516 in Patients With VHL Syndrome Associated TumorsWho this might be right forVon Hippel Lindau-Deficient Clear Cell Renal Cell Carcinoma Jiangsu Hansoh Pharmaceutical Co., Ltd. 60
Testing effectiveness (Phase 2)Active Not RecruitingNCT03401788What this trial is testingBelzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482-004)Who this might be right forVHL - Von Hippel-Lindau SyndromeVHL Gene MutationVHL Syndrome+3 more Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) 50